INSM Stock Forecast: Insmed, Inc. Price Predictions for 2026-2027
The 24 Wall Street analysts covering Insmed, Inc. hold a median 12-month price target of $195 — +38.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Insmed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
INSM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INSM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +38.0% from it.
Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Nov 2026 | HC Wainwright & Co. | Assumes | Buy | $220 |
| 2 Nov 2026 | Guggenheim | Maintains | Buy | $205 → $201 |
| 21 Oct 2026 | Morgan Stanley | Maintains | Overweight | $218 → $213 |
| 12 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $220 |
| 12 Oct 2026 | Wolfe Research | Downgrade | Peer Perform | — |
| 30 Sept 2026 | Barclays | Maintains | Overweight | $237 → $207 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $188 |
| 15 Sept 2026 | Roth Capital | Reiterates | Buy | $212 → $198 |
| 10 Aug 2026 | JP Morgan | Maintains | Overweight | $179 → $175 |
| 10 Aug 2026 | Truist Securities | Reiterates | Buy | $185 → $195 |
| 7 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $160 → $170 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $207 → $205 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $161 → $169 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | $192 |
| 15 July 2026 | Wells Fargo | Maintains | Overweight | $160 → $161 |
| 10 July 2026 | Guggenheim | Reiterates | Buy | $207 |
| 22 June 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 5 June 2026 | RBC Capital | Maintains | Outperform | — |
| 14 May 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INSM.
This page is one stock. Monday covers all of them.
INSM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
INSM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Insmed, Inc. returned −29.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
INSM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 21.1×
- Price / book
- 44.1×
- EV / EBITDA
- —
Cheaper than 7% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 84.2%
- Operating margin
- −41.7%
- Net margin
- —
Higher than 93% of US stocks
Higher than 19% of US stocks
- Return on equity
- −72.5%
- Return on assets
- −17.3%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Insmed, Inc. has a market value of $31.7B and an enterprise value of $31.3B.
Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 296.1% year on year.
Net income over the same four quarters: −$875.3M, a −76.9% net margin.
Diluted earnings per share, trailing twelve months: −$4.11.
Free cash flow in the twelve months to 30 June 2026: −$807.7M.
forward P/E: 227.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Insmed, Inc. employs 1,664 people — $684K of revenue per employee.
Data provided by Twelve Data
INSM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at INSM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Insmed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about INSM
What is the INSM stock price forecast for 2026-2027?
The 24 Wall Street analysts covering Insmed, Inc. have a median 12-month price target of $195, with estimates ranging from $158 to $243. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is INSM stock a buy right now?
Of the 24 analysts covering Insmed, Inc., 23 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insmed, Inc. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INSM?
As at 21 Nov 2026, Insmed, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
Will INSM stock go up?
No one can know that. What the data says: the median 12-month target from 24 analysts implies +38.0% from the last close, and Ticker Nerd's factor model ranks Insmed, Inc. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the INSM stock forecast for 2030?
No analyst covering Insmed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $158 to $243 over the next 12 months.
How has INSM stock performed over the past year?
Insmed, Inc. returned -29.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Insmed, Inc. do?
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions.
About Insmed, Inc.
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along with clinical-stage programs focused on pulmonary and inflammatory conditions. The company’s pipeline emphasizes innovative approaches such as oral therapies and inhaled medicines designed to address difficult-to-treat respiratory disorders. Insmed also conducts research across multiple scientific platforms, including protein engineering and other advanced drug-development technologies. Headquartered in Bridgewater, New Jersey, Insmed serves patients and healthcare providers in the United States, Europe, Japan, and other international markets, positioning itself as a specialist in rare-disease and specialty respiratory treatment.
CEO Mr. William H. Lewis J.D., M.B.A. · 1,664 employees · United States · https://www.insmed.com